John Overdeck’s Flexion Therapeutics, Inc. FLXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-49,056
| Closed | -$299K | – | 5131 |
|
|
2021
Q3 | $299K | Sell |
49,056
-444,529
| -90% | -$2.77M | ﹤0.01% | 3674 |
|
|
2021
Q2 | $4.06M | Sell |
493,585
-416,472
| -46% | -$3.54M | 0.01% | 1324 |
|
|
2021
Q1 | $8.14M | Buy |
910,057
+719,383
| +377% | +$8.25M | 0.02% | 797 |
|
|
2020
Q4 | $2.2M | Buy |
190,674
+32,200
| +20% | +$374K | 0.01% | 1439 |
|
|
2020
Q3 | $1.65M | Buy |
+158,474
| New | +$1.94M | 0.01% | 1418 |
|
|
2020
Q2 | – | Sell |
-216,163
| Closed | -$1.7M | – | 3724 |
|
|
2020
Q1 | $1.7M | Buy |
216,163
+80,937
| +60% | +$1.22M | 0.01% | 1057 |
|
|
2019
Q4 | $2.8M | Buy |
+135,226
| New | +$2.28M | 0.01% | 1330 |
|
|
2019
Q2 | – | Sell |
-71,095
| Closed | -$887K | – | 3801 |
|
|
2019
Q1 | $887K | Buy |
+71,095
| New | +$950K | ﹤0.01% | 1901 |
|
|
2018
Q1 | – | Sell |
-24,032
| Closed | -$602K | – | 3662 |
|
|
2017
Q4 | $602K | Buy |
+24,032
| New | +$588K | ﹤0.01% | 2307 |
|
|
2017
Q2 | – | Sell |
-27,306
| Closed | -$735K | – | 3401 |
|
|
2017
Q1 | $735K | Buy |
+27,306
| New | +$557K | ﹤0.01% | 2104 |
|
|
2015
Q2 | – | Sell |
-34,253
| Closed | -$771K | – | 3199 |
|
|
2015
Q1 | $771K | Sell |
34,253
-7,560
| -18% | -$175K | ﹤0.01% | 1738 |
|
|
2014
Q4 | $844K | Buy |
+41,813
| New | +$758K | ﹤0.01% | 1465 |
|
John Overdeck's FLXN Position: Q4 2021 in Review
John Overdeck sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 49,056 shares — an estimated $299K sold.
John Overdeck first reported a position in FLXN in Q4 2014 and held it in 12 quarters. The position peaked at $8.14M in Q1 2021. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.
- John Overdeck reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
- John Overdeck sold 49,056 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $299K.
- John Overdeck first reported a position in Flexion Therapeutics, Inc. in Q4 2014 and held it in 12 quarters.
- John Overdeck's Flexion Therapeutics, Inc. position peaked at $8.14M in Q1 2021.
- 1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.
Based on Two Sigma Investments's 13F filing for Q4 2021, filed 14 Feb 2022.